Ubs Group Ag Anixa Biosciences Inc Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Ubs Group Ag holds 524,162 shares of ANIX stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

524,162

Previous 534,124 1.87%

Holding current value

$1.79 Million

Previous $1.32 Million 13.22%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$2.13 - $3.29 $21,219 - $32,774	-9,962 Reduced 1.87%	524,162 $1.5 Million
Q4 2024 Feb 14, 2025	BUY	$2.48 - $3.97 $11,720 - $18,762	4,726 Added 0.89%	534,124 $1.32 Million
Q3 2024 Nov 14, 2024	SELL	$2.21 - $3.48 $2,523 - $3,974	-1,142 Reduced 0.22%	529,398 $1.67 Million
Q2 2024 Aug 13, 2024	SELL	$2.21 - $3.35 $12,745 - $19,319	-5,767 Reduced 1.08%	530,540 $1.17 Million
Q1 2024 May 13, 2024	SELL	$3.08 - $5.02 $136,354 - $222,240	-44,271 Reduced 7.63%	536,307 $1.67 Million
Q4 2023 Feb 09, 2024	SELL	$2.85 - $4.19 $68,003 - $99,977	-23,861 Reduced 3.95%	580,578 $2.25 Million
Q3 2023 Nov 09, 2023	SELL	$2.97 - $3.87 $88,624 - $115,480	-29,840 Reduced 4.7%	604,439 $1.98 Million
Q2 2023 Aug 11, 2023	SELL	$3.0 - $5.97 $14,151 - $28,160	-4,717 Reduced 0.74%	634,279 $2.03 Million
Q1 2023 May 12, 2023	BUY	$3.86 - $5.0 $63,504 - $82,260	16,452 Added 2.64%	638,996 $2.75 Million
Q4 2022 Feb 08, 2023	BUY	$3.78 - $5.81 $3,224 - $4,955	853 Added 0.14%	622,544 $2.65 Million
Q3 2022 Nov 10, 2022	BUY	$2.81 - $6.15 $45,760 - $100,152	16,285 Added 2.69%	621,691 $3.06 Million
Q2 2022 Aug 10, 2022	BUY	$2.55 - $4.1 $17,760 - $28,556	6,965 Added 1.16%	605,406 $1.85 Million
Q1 2022 May 16, 2022	BUY	$2.5 - $3.42 $6,605 - $9,035	2,642 Added 0.44%	598,441 $1.64 Million
Q4 2021 Feb 14, 2022	BUY	$2.88 - $5.5 $38,566 - $73,650	13,391 Added 2.3%	595,799 $1.77 Million
Q3 2021 Nov 15, 2021	SELL	$3.57 - $5.6 $374,471 - $587,406	-104,894 Reduced 15.26%	582,408 $2.78 Million
Q2 2021 Aug 13, 2021	BUY	$3.46 - $4.92 $345,380 - $491,119	99,821 Added 16.99%	687,302 $2.67 Million
Q1 2021 May 12, 2021	SELL	$3.27 - $7.14 $100,591 - $219,640	-30,762 Reduced 4.98%	587,481 $2.75 Million
Q4 2020 Feb 11, 2021	BUY	$1.94 - $3.19 $174,988 - $287,738	90,200 Added 17.08%	618,243 $1.9 Million
Q3 2020 Nov 12, 2020	BUY	$1.79 - $3.3 $12,977 - $23,925	7,250 Added 1.39%	528,043 $1.28 Million
Q2 2020 Jul 31, 2020	BUY	$1.53 - $3.06 $274,096 - $548,192	179,148 Added 52.44%	520,793 $1.59 Million
Q1 2020 May 01, 2020	BUY	$1.35 - $4.06 $68,289 - $205,375	50,585 Added 17.38%	341,645 $543,000
Q4 2019 Feb 14, 2020	BUY	$2.78 - $4.03 $83,447 - $120,968	30,017 Added 11.5%	291,060 $955,000
Q3 2019 Nov 14, 2019	BUY	$3.53 - $4.7 $96,369 - $128,310	27,300 Added 11.68%	261,043 $1.04 Million
Q2 2019 Aug 14, 2019	BUY	$3.47 - $4.75 $93,690 - $128,250	27,000 Added 13.06%	233,743 $848,000
Q1 2019 May 14, 2019	BUY	$3.85 - $5.53 $147,840 - $212,352	38,400 Added 22.81%	206,743 $934,000
Q4 2018 Feb 14, 2019	BUY	$3.37 - $6.59 $567,315 - $1.11 Million	168,343 New	168,343 $663,000

Others Institutions Holding ANIX

# of Institutions

Shares Held

5.49M

Call Options Held

24.5K

Put Options Held

23.4K

View Full List

About Anixa Biosciences Inc

Ticker ANIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,661,700
Market Cap $105M
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...

More about ANIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account